Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:1346

Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017


Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $2,000.00
Meta Description No
Publisher GlobalData
Date of Report Dec 4, 2011
Quick Overview
Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global diabetic foot ulcer market. The report identifies the key trends shaping and driving the global diabetic foot ulcer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global diabetic foot ulcer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the global diabetic foot ulcer (DFU) therapeutics market to be worth $1,154m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 10.2% to reach $2,275m by 2017. DFU therapeutics market is contributed by DFI therapeutics market and DFU Wound healing products. The DFI therapeutic market holds the major share of $1,127m of the total DFU therapeutics market. While DFU wound healing therapeutics market is worth only $26m. This high growth forecast is primarily attributed to an increase in the diabetic patient population which will lead to increases in DFU incidence and prevalence, along with emergence of more therapeutic options. The strong product pipeline will complement the existing products by providing effective treatment options.

Scope

The report provides information on the key drivers and challenges of the diabetic foot ulcer market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) diabetic foot ulcer market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as angiotensin analog, topoisomerases inhibitor, PKC modulator, PDGF modulator, adenosine A2a receptor agonist, cytokines modulater, protein synthesis inhibitor, Antithrombin III activator, cell wall or cell membrane integrity disruptor, Immune system activator, plasmin activator, perivascular supporting agent, angiogenesis stimulator.
- Analysis of the current and future competition in the seven key countries diabetic foot ulcer market. Key market players covered are Pfizer Inc., Genaera Corporation and Cardiovascular Biotherapeutics, Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the diabetic foot ulcer therapeutics market.
- Analysis of key recent licensing and partnership agreements in diabetic foot ulcer market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global diabetic foot ulcer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global diabetic foot ulcer market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global diabetic foot ulcer market landscape? – Identify, understand and capitalize.
Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Diabetic Foot Ulcer (DFU) Therapeutics: Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 9
2.4 Symptoms 9
2.5 Diagnosis 10
2.5.1 History and Physical Examination 10
2.5.2 Laboratory Tests 10
2.6 Treatment and Management Pattern 10
2.6.1 Management of Co-morbidities 10
2.6.2 Evaluation of Vascular Status 10
2.6.3 Tissue Management 11
2.7 GlobalData Pipeline Report Guidance 12
3 DFU Therapeutics: Market Characterization 13
3.1 DFU Therapeutics Global Market Size 13
3.2 DFU Therapeutics Market Forecast 15
3.3 DFU Therapeutics Market Size – The US (2005-2010) 17
3.4 DFU Therapeutics Market Forecast – The US (2010-2017) 19
3.5 DFU Therapeutics Market Size – France (2005-2010) 21
3.6 DFU Therapeutics Market Forecast – France (2010-2017) 23
3.7 DFU Therapeutics Market Size – Germany (2005-2010) 25
3.8 DFU Therapeutics Market Forecast – Germany (2010-2017) 27
3.9 DFU Therapeutics Market Size - Italy (2005-2010) 29
3.10 DFU Therapeutics Market Forecast - Italy (2010-2017) 31
3.11 DFU Therapeutics Market Size – Spain (2005-2010) 33
3.12 DFU Therapeutics Market Forecast – Spain (2010-2017) 35
3.13 DFU Therapeutics Market Size – The UK (2005-2010) 37
3.14 DFU Therapeutics Market Forecast – The UK (2010-2017) 39
3.15 DFU Therapeutics Market Size - Japan (2005-2010) 41
3.16 DFU Therapeutics Market Forecast – Japan (2010-2017) 43
3.17 Drivers and Restraints for the DFU Therapeutics Market 45
3.17.1 Drivers of the DFU Therapeutics Market 45
3.17.2 Barriers for DFU Therapeutics Market 45
3.18 Opportunity and Unmet Need Analysis 46
3.19 Key Takeaway 46
4 DFU Therapeutics: Competitive Assessment 47
4.1 Overview 47
4.2 Strategic Competitor Assessment 47
4.3 Major Marketed Product Profiles in DFU Therapeutics Market 48
4.3.1 Invanz (ertapenam) 48
4.3.2 Regranex (becaplermin) 49
4.3.3 Zyvox (linezolid) 50
4.3.4 Zosyn (piperacillin/tazobactam) 51
4.4 Key Takeaway 52
5 DFU Therapeutics: Pipeline Assessment 53
5.1 Overview 53
5.2 Strategic Pipeline Assessment 53
5.2.1 Technology Trends Analytic Framework 53
5.3 DFU Therapeutics – Pipeline by Phases of Development 54
5.3.1 DFU Therapeutics – Phase III Pipeline 54
5.3.2 DFU Therapeutics – Phase II Pipeline 55
5.3.3 DFU Therapeutics – Phase I Pipeline 55
5.3.4 DFU Therapeutics – Preclinical/ Discovery Clinical Pipeline 55
5.4 DFU Therapeutics – Pipeline by Mechanism of Action 56
5.5 Technology Trends Analytic Framework 57
5.6 DFU Therapeutics– Most Promising Drugs under Clinical Development 58
5.7 Most Promising Drugs Profile 59
5.7.1 Pexiganan (pexiganan acetate) 59
5.7.2 Fragmin (Dalteparin Sodium) 59
5.7.3 CVBT-141B (FGF-1) 60
5.8 Key Takeaway 61
6 DFU Therapeutics: Clinical Trials Mapping 62
6.1 Clinical Trials by Region/Country (US, EU-5 and Japan) 62
6.2 Clinical Trials by Phase 63
6.3 Clinical Trials by Trial Status 64
6.4 Prominent Sponsors 65
6.5 Top Ten Companies Participating in Therapeutics Clinical Trials 66
7 DFU Therapeutics: Strategic Assessment 68
7.1 Key Events impacting the Future Market 68
7.2 Future Market Competition Scenario 68
8 DFU Therapeutics: Future Players 70
8.1 Introduction 70
8.2 Company Profiles 70
8.2.1 Pfizer Inc. 70
8.2.2 Genaera Corporation 74
8.2.3 Cardiovascular Biotherapeutics, Inc 75
8.2.4 Tabular Presentation Details of Other Companies in the Pipeline 76
9 DFU Therapeutics: Licensing & Partnership Deals 82
10 DFU Therapeutics: Appendix 84
10.1 Definitions 84
10.2 Acronyms 84
10.3 Research Methodology 85
10.3.1 Coverage 85
10.3.2 Secondary Research 85
10.3.3 Forecasting 86
10.3.4 Primary Research 89
10.3.5 Expert Panels 89
10.4 Contact Us 89
10.5 Disclaimer 89
10.6 Bibliography 90




...